Year-end report: Clear signs of favourable market trends after a challenging 2021 - Enzymatica AB

Significant events in Q4

Other events in Q4

- The Extraordinary General Meeting on October 18, 2021, resolved to approve an incentive program for CEO Claus Egstrand through an employee option plan, a directed issue of warrants and a transfer of warrants.

- On November 2, 2021, the Board of Directors reached a decision on financial targets for the company. Net sales in 2026 will amount to at least SEK 600 million with an EBIT margin of at least 28 %.

- No significant events were reported after the end of the quarter.

- Enzymatica's partner Sanofi received approval from the health authorities in Mexico (Cofepris) and Turkey (TITCK), which enabled the launch of ColdZyme in these markets.

- In December, ColdZyme was approved as a "Natural Health Product" by the Canadian authorities (Health Canada).

- In December, the Patent Office in Mexico issued a preliminary ruling that it intends to grant Enzymatica a patent for the cod trypsin that is one of the key components in ColdZyme. Final approval is expected to be granted during the first half of 2022 and the patent will be valid until 2036.

- Through the agreement with STADA, in the fourth quarter Enzymatica gained sales to Finland, Poland, the Balkans, the Netherlands, Greece, and to six new markets: Cyprus, Moldavia, Azerbaijan, Georgia, Armenia and Mongolia.

Q4

January-December

- Net sales reached SEK 18.7 (42.3) million.

- The result for the period was SEK -10.8 million (-0.3).

- Earnings per share, basic and diluted, were SEK -0.07 (0.00).

- Cash flow from operating activities for the period totalled SEK -6.1 (-8.2) million.

- Net sales reached SEK 57.2 (111.2) million.

- The result for the period was SEK -45.4 million (-13.2).

- Earnings per share, basic and diluted, were SEK -0.31 (-0.09).

- Cash flow from operating activities for the period totalled

 - SEK -35.4 (-10.7) million.

- Net debt totalled SEK -29.0 (-9.2) million.